Differential effects in cardiovascular markers between high-dose angiotensin II receptor blocker monotherapy and combination therapy of ARB with calcium channel blocker in hypertension (DEAR Trial)

Kenichiro Kinouchi, Atsuhiro Ichihara, Kanako Bokuda, Hideaki Kurosawa, Hiroshi Itoh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aims. Arterial stiffness is an independent risk factor for cardiovascular morbidity and mortality. This study was conducted to determine the effect of olmesartan (OLM) and azelnidipine (AZL) on arterial stiffness using the cardio-ankle vascular index (CAVI), which is a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods. Fifty-two consecutive hypertensive patients were randomly assigned either to a group treated with OLM monotherapy or to a group treated with OLM and AZL combination therapy. Clinical and biological parameters were measured before and 12 months after the start of this study. Results. Both therapies significantly and similarly reduced BP, augmentation index, and plasma aldosterone levels. The combination therapy significantly decreased CAVI and serum low-density lipoprotein (LDL-C) levels and these reductions were significantly greater than those produced with monotherapy. No significant differences in metabolic parameters were observed between the two therapies. Conclusion. The combination therapy with OLM and AZL had beneficial effects on arterial stiffness assessed by CAVI, LDL-C, and metabolism, despite the similar BP reduction, compared with OLM monotherapy. Since these markers are known to influence the future risk of cardiovascular events, combination therapy with OLM and AZL could be a useful choice for treating hypertensive patients.

Original languageEnglish
Article number284823
JournalInternational Journal of Hypertension
Volume2011
DOIs
Publication statusPublished - 2011

Fingerprint

Angiotensin Receptor Antagonists
Calcium Channel Blockers
Vascular Stiffness
Hypertension
Ankle
Blood Vessels
Blood Pressure
Therapeutics
Aldosterone
LDL Lipoproteins
olmesartan
Morbidity
Mortality
azelnidipine
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{d4dfe64de58e4e03b8388d6f77fe6452,
title = "Differential effects in cardiovascular markers between high-dose angiotensin II receptor blocker monotherapy and combination therapy of ARB with calcium channel blocker in hypertension (DEAR Trial)",
abstract = "Background/Aims. Arterial stiffness is an independent risk factor for cardiovascular morbidity and mortality. This study was conducted to determine the effect of olmesartan (OLM) and azelnidipine (AZL) on arterial stiffness using the cardio-ankle vascular index (CAVI), which is a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods. Fifty-two consecutive hypertensive patients were randomly assigned either to a group treated with OLM monotherapy or to a group treated with OLM and AZL combination therapy. Clinical and biological parameters were measured before and 12 months after the start of this study. Results. Both therapies significantly and similarly reduced BP, augmentation index, and plasma aldosterone levels. The combination therapy significantly decreased CAVI and serum low-density lipoprotein (LDL-C) levels and these reductions were significantly greater than those produced with monotherapy. No significant differences in metabolic parameters were observed between the two therapies. Conclusion. The combination therapy with OLM and AZL had beneficial effects on arterial stiffness assessed by CAVI, LDL-C, and metabolism, despite the similar BP reduction, compared with OLM monotherapy. Since these markers are known to influence the future risk of cardiovascular events, combination therapy with OLM and AZL could be a useful choice for treating hypertensive patients.",
author = "Kenichiro Kinouchi and Atsuhiro Ichihara and Kanako Bokuda and Hideaki Kurosawa and Hiroshi Itoh",
year = "2011",
doi = "10.4061/2011/284823",
language = "English",
volume = "2011",
journal = "International Journal of Hypertension",
issn = "2090-0384",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Differential effects in cardiovascular markers between high-dose angiotensin II receptor blocker monotherapy and combination therapy of ARB with calcium channel blocker in hypertension (DEAR Trial)

AU - Kinouchi, Kenichiro

AU - Ichihara, Atsuhiro

AU - Bokuda, Kanako

AU - Kurosawa, Hideaki

AU - Itoh, Hiroshi

PY - 2011

Y1 - 2011

N2 - Background/Aims. Arterial stiffness is an independent risk factor for cardiovascular morbidity and mortality. This study was conducted to determine the effect of olmesartan (OLM) and azelnidipine (AZL) on arterial stiffness using the cardio-ankle vascular index (CAVI), which is a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods. Fifty-two consecutive hypertensive patients were randomly assigned either to a group treated with OLM monotherapy or to a group treated with OLM and AZL combination therapy. Clinical and biological parameters were measured before and 12 months after the start of this study. Results. Both therapies significantly and similarly reduced BP, augmentation index, and plasma aldosterone levels. The combination therapy significantly decreased CAVI and serum low-density lipoprotein (LDL-C) levels and these reductions were significantly greater than those produced with monotherapy. No significant differences in metabolic parameters were observed between the two therapies. Conclusion. The combination therapy with OLM and AZL had beneficial effects on arterial stiffness assessed by CAVI, LDL-C, and metabolism, despite the similar BP reduction, compared with OLM monotherapy. Since these markers are known to influence the future risk of cardiovascular events, combination therapy with OLM and AZL could be a useful choice for treating hypertensive patients.

AB - Background/Aims. Arterial stiffness is an independent risk factor for cardiovascular morbidity and mortality. This study was conducted to determine the effect of olmesartan (OLM) and azelnidipine (AZL) on arterial stiffness using the cardio-ankle vascular index (CAVI), which is a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods. Fifty-two consecutive hypertensive patients were randomly assigned either to a group treated with OLM monotherapy or to a group treated with OLM and AZL combination therapy. Clinical and biological parameters were measured before and 12 months after the start of this study. Results. Both therapies significantly and similarly reduced BP, augmentation index, and plasma aldosterone levels. The combination therapy significantly decreased CAVI and serum low-density lipoprotein (LDL-C) levels and these reductions were significantly greater than those produced with monotherapy. No significant differences in metabolic parameters were observed between the two therapies. Conclusion. The combination therapy with OLM and AZL had beneficial effects on arterial stiffness assessed by CAVI, LDL-C, and metabolism, despite the similar BP reduction, compared with OLM monotherapy. Since these markers are known to influence the future risk of cardiovascular events, combination therapy with OLM and AZL could be a useful choice for treating hypertensive patients.

UR - http://www.scopus.com/inward/record.url?scp=84868295034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868295034&partnerID=8YFLogxK

U2 - 10.4061/2011/284823

DO - 10.4061/2011/284823

M3 - Article

C2 - 21755034

AN - SCOPUS:84868295034

VL - 2011

JO - International Journal of Hypertension

JF - International Journal of Hypertension

SN - 2090-0384

M1 - 284823

ER -